Jump to ContentJump to Main Navigation
The Lock and Key of MedicineMonoclonal Antibodies and the Transformation of Healthcare$
Users without a subscription are not able to see the full content.

Lara V Marks

Print publication date: 2015

Print ISBN-13: 9780300167733

Published to Yale Scholarship Online: January 2016

DOI: 10.12987/yale/9780300167733.001.0001

Show Summary Details
Page of

PRINTED FROM YALE SCHOLARSHIP ONLINE (www.yale.universitypressscholarship.com). (c) Copyright Yale University Press, 2018. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a monograph in YSO for personal use (for details see www.yale.universitypressscholarship.com/page/privacy-policy).date: 19 November 2018

Blockbuster Mab Drugs

Blockbuster Mab Drugs

Chapter:
(p.184) Chapter Nine Blockbuster Mab Drugs
Source:
The Lock and Key of Medicine
Author(s):

Lara V. Marks

Publisher:
Yale University Press
DOI:10.12987/yale/9780300167733.003.0009

This chapter explores the development of rituximab and infliximab, two of the best-selling monoclonal antibody (Mab) therapeutics today. The evolution of these drugs not only illustrates how a single Mab therapeutic came to be used for multiple indications, but shows the significant role that Mabs have played in fostering new understandings of the causes of cancer and autoimmune disorders, thereby opening avenues to more effective care. Their stories also show how the development of Mab drugs shifted from prioritizing rare diseases to treating more lucrative common illnesses. Although each drug took a different path to the clinic, they encountered similar hurdles along the way. These included not only the challenge of scaling up production for newly engineered antibodies, and getting Mabs through clinical trials and regulatory approval, but also securing enough funding. All of this required a complex alliance among academic researchers, industry leaders, and financiers as well as the consent of patients.

Keywords:   rituximab, infliximab, Mabs, monoclonal antibodies, Mab drugs, drug development, anti-cancer drugs, autoimmune disorders

Yale Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us.